ArriVent BioPharma (AVBP) Insider Chris Nolet Buys 13,562 Shares

Insider Buying and Selling at ArriVent BioPharma, Inc.

On June 18, 2026, Chris Nolet bought 13,562 shares of AVBP (NasdaqGM), valued at about $442,000 based on a share price of $32.7. This purchase reflects a growing confidence among insiders in the company’s future.

Multiple Insiders Join the Buying Trend

On the same day, other insiders also purchased shares. Merdad Parsey and John Hohneker each bought 13,562 shares of AVBP. This collective buying suggests a strong belief in the company's direction among its leadership.

Stock Performance and Market Context

AVBP's stock has fluctuated between $17.00 and $35.83 over the past year, with a recent close at $28.90. The shares are currently trading above their 50-day moving average of $30.28, indicating some bullish momentum. Given the recent insider purchases and the stock's position, it may attract more attention from investors.

Analysts Set New Price Targets

Analysts have expressed optimism about AVBP, maintaining a strong buy rating. On October 8, 2026, HC Wainwright & Co. kept its buy rating with a price target of $27.0, while Citigroup also maintained a buy rating with a target of $20.0 on October 7, 2026. The consensus from ten analysts suggests a mean price target of $44.7, indicating significant upside potential based on current market sentiment.

What AVBP Does

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs in cancer. The company’s lead candidate is firmonertinib, which targets specific mutations in non-small cell lung cancer. The insider purchases may signal confidence in the progress of their clinical trials and future prospects.

What’s Next for AVBP

Investors will be watching closely as AVBP prepares for its next earnings report on November 16, 2026. The recent insider buying activity, along with analyst support, could set the stage for increased interest in the stock. It’s important to remember that insider trades reflect past positions and may not represent current holdings, as the company's 13F filings provide a snapshot of holdings as of the reporting period.